Board member and CEO
Giulio Bianchini, Ph.D (ext.)
Co-founder and Scientific Advisor
Nadia Freato, Ph.D
Clinical project manager
Laura Bertocchi, Ph.D
Formulation development manager
Susanna Spini (ext.)
Regulatory Affairs/Quality Assurance
Andrea Senaldi is a seasoned executive with 20 years experience in the Healthcare industry. Between 2004 and 2011 he was SVP and CFO at DiaSorin an outperforming company in IVD.
Prior to that, he has covered several executive positions in the FMCG industry. More recently, he gathered additional experience with early stage Medtech companies, as Founder and Managing Partner at Valuemaze, an advisor to SMEs on strategy definition/deployment and M&A execution.
In 2019 and 2020, he was Chief Executive Officer at Diadem, an IVD company committed to the development of a test which enables prediction, monitoring, diagnosis and successful drug development for Alzheimer’s Disease.
Andrea holds a Degree in economics and finance.
Giulio Bianchini, Ph.D
Giulio obtained his PhD in Chemical Sciences at Ca’ Foscari Venezia University (IT) working on photochemical and supramolecular tuned catalysis and, during his post-doc at the School of Chemistry University of Bristol (UK), he improved his know-how in the design, synthesis, and characterisation of catalytic systems.
Giulio joined Jointherapeutics in 2015 and worked on the development of new polysaccharide derivatives for regenerative medicine purposes and on products derived thereof.
Imaginative but always careful on IP, scientific, regulatory, and technical aspects, he enjoys the highly dynamic environment of start-ups.
Giulio is co-founder of GlycoCore Pharma S.r.l.
Nadia Freato, Ph.D
Nadia graduated in Biology, followed by a Master’s degree in Functional Genomics at University of Triest, Italy.
She obtained her PhD in Biochemistry at Utrecht University working at Sanquin Institute in Amsterdam, The Netherlands. During her PhD, Nadia studied the structure/function of various coagulation proteins and became an expert of protein structures, Hydrogen Deuterium eXchange Mass Spectrometry (HDX-MS), SPR and other biochemical and cellular techniques.
She also worked as a post-doc at Sanquin Institute in Amsterdam on the profiling of immunoglobulins via targeted Mass Spectrometry. The level of her research led to publications in high impact factor journals.
She is currently the Clinical Project Manager of GlycoCore Pharma S.r.l.
Laura Bertocchi, Ph.D
Laura Bertocchi graduated in Pharmaceutical Chemistry and Technology at University of Parma in 2018. The project of her thesis aimed at the investigation of mannitol as drug carrier in formulations for dry powder inhalers.
After graduation, Laura continued her education in pharmaceutical technology attending the PhD course in “Drug, Biomolecules and Health Products” under the supervision of Professor Ruggero Bettini at University of Parma. During the PhD course, Laura has deepened her knowledge about formulations for inhalation, particularly investigating sodium hyaluronate as constituent polymer for the preparation of nano-embedded microparticles for pulmonary drug delivery.
She attended the lab of Professor Carsten Ehrhardt at Trinity College Dublin as visiting PhD student, investigating the effect of nanoparticles on pulmonary cell lines.
Laura is the Formulation Development Manager of GlycoCore Pharma S.r.l.
Consultant – Quality and Regulatory Compliance for Medical Devices and PRRC art. 15 Regulation EU 745/2017
Lead Auditor – Auditor ISO 13485
Lead Auditor – Auditor ISO 9001, ISO 45001, ISO 14001
Auditor ISO 50001
Quality Systems designer ISO 9001, ISO 13485 and Integrated QHSE (ISO 9001, ISO 45001, ISO 14001, ISO 50001)
After 30 years as employee of pharmaceutical companies moving from non-clinical to clinical research, design and development as well as from regulatory affairs to vigilance of medical devices, now she puts her experiences to good use by letting herself be involved in ever new and stimulating realities as quality assurance, regulatory affairs and Person Responsible of Regulatory Compliance in accordance with art. 15 Regulation EU 745/2017